SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021 Oct 6, 2021 07:00AM
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19 Oct 4, 2021 07:00AM
SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer Sep 28, 2021 07:00AM
SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19 (BCYP) Sep 24, 2021 07:01AM
SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19 Sep 24, 2021 07:00AM


Sep 22, 2021 07:03AM Big Cypress Acquisition (BCYP) and SAB Biotherapeutics Awarded Additional $60.5M from BARDA and US DoD for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19
Sep 22, 2021 07:00AM SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19
Sep 15, 2021 07:00AM SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza
Sep 8, 2021 07:00AM SAB Biotherapeutics to Present at Upcoming September Virtual Investor Conferences
Aug 11, 2021 07:02AM SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants (BCYP)
Aug 11, 2021 07:00AM SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants
Jul 9, 2021 07:00AM SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021
Jul 8, 2021 05:14PM SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants (BCYP)
Jul 8, 2021 07:06AM SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants
Jul 8, 2021 07:06AM SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants
Jul 2, 2021 07:47AM SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza
Jun 29, 2021 07:00AM SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza
Jun 22, 2021 06:23AM SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition (BCYP)
Jun 22, 2021 06:00AM SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerg